All Stories

  1. How safe are the TNF alpha inhibitors with respect to pregnancy outcomes in autoimmune diseases?
  2. Assessment of intrinsic capacity using step 2 assessment tools of the integrated care for older people (ICOPE) care in the elderly population living in the Chengalpattu region
  3. Brahmi (Bacopa monnieri) plant preparation facilitates to enhance the activities of dendritic cells to control non-small cell lung cancer (NSCLC)
  4. Retraction Note: Exploring the immunomodulatory potential of brahmi (Bacopa monnieri) in the treatment of invasive ductal carcinoma
  5. Role of Trichostatin A (TSA) in modulating the epigenetic modification in the lymphocytes of colorectal cancer (CRC)
  6. Interferon-alpha 2b (IFNα2b) enhances monocyte-derived dendritic cell maturation and Th1-skewed anti-tumor immunity in non-small cell lung cancer
  7. Epigenetic control of T helper cells differentiation: a mechanistic insight into the association between acute leukemia and coronary artery disease
  8. Advancing therapeutic approaches and shaping future perspectives in the management of autosomal dominant polycystic kidney disease (ADPKD): Insights from clinical trials
  9. Overcoming barriers to unlock the therapeutic potential of saroglitazar for the management of metabolic dysfunction-associated steatotic liver disease
  10. Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations
  11. Exploring the immunomodulatory potential of Brahmi (Bacopa monnieri) in the treatment of invasive ductal carcinoma
  12. Immunomodulatory effects of Diospyros peregrina fruit preparation (DFP) in non-small cell lung cancer (NSCLC) by utilizing dendritic cell-mediated antigen presentation and T helper (TH) cell differentiation
  13. Prediction of maternal and foetal outcomes among patients with preeclampsia using circulatory biomarkers (MMP-9 & ST2) - A prospective cohort study
  14. Fathoming the Role of Semaglutide in Obesity Therapeutics
  15. Depletion of enhancer zeste homolog 2 (EZH2) directs transcription factors associated with T cell differentiation through epigenetic regulation of Yin Yang 1(YY1) in combating non-small cell lung cancer (NSCLC)
  16. Differential Expression of Caveolin-3, Suppression of Tumorigenicity 2, and Growth Differentiation Factor-15 Genes and Their Association with Acute Myocardial Infarction: A Cross-Sectional Study in a Multi-Specialty Hospital in Tamil Nadu
  17. Role of Diospyros peregrina fruit preparation in suppressing regulatory T (Treg) cells in the tumor microenvironment of breast and lung cancer
  18. EVALUATION OF ADENOVIRAL VECTOR-BASED VACCINES FOR PREVENTION OF COVID-19 – AN OVERVIEW
  19. Extent of knowledge and attitudes on plagiarism among undergraduate medical students in South India - a multicentre, cross-sectional study to determine the need for incorporating research ethics in medical undergraduate curriculum
  20. Usefullness of MicroRNAs in Predicting the Clinical Outcome of Patients with Acute Myocardial Infarction During Follow-Up: A Systematic Review
  21. Efficacy of pharmacological interventions in COVID‐19: A network meta‐analysis
  22. Evaluation of pharmacological interventions in the management of adenomyosis: a systematic review
  23. Alirocumab in Post ACS Patients - Saving Lives at a Premium
  24. A Review of The Contribution of Gut-Dependent Microbiota Derived Marker, Trimethylamine N-oxide (TMAO), in Coronary Artery Disease
  25. Long Term Prognostic Utility of Matrix Metalloproteinase-9 in Patients with Acute Coronary Syndrome - A Systematic Review
  26. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges
  27. Novel and Re-emerging Zoonotic Viral Diseases in India during Last Two Decades: An Overview
  28. Avaliação da Senescência de Células Sanguíneas Mononucleares Periféricas e na Disfunção Endotelial entre Adultos com Alto Risco Cardiovascular
  29. The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy
  30. Novel approaches in the treatment of diabetic cardiomyopathy
  31. Prognostic role of soluble ST2 in acute coronary syndrome with diabetes
  32. Effect of metformin on exercise capacity in metabolic syndrome
  33. Authors reply to “No, we are not—we keep forgetting the right ventricle”
  34. Do ANGPTL-4 and galectin-3 reflect the severity of coronary artery disease?
  35. Homocysteine-Is there any role in Coronary Heart Disease?
  36. A peek into the drug development scenario of endometriosis – A systematic review
  37. SCARB1 rs5888 c.1050C>T Polymorphism and the Risk of Hypercholesterolemia and Myocardial Infarction in Indian Tamil Population
  38. End points in heart failure—are we doing it right?
  39. Molecular analysis of the LDLR gene in coronary artery disease patients from the Indian population
  40. Effect of tolvaptan on acute heart failure with hyponatremia – A randomized, double blind, controlled clinical trial
  41. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition—The Dream of Translational Medicine
  42. GDF 15 - A Novel Biomarker in the Offing for Heart Failure
  43. Value of pentraxin-3 and galectin-3 in acute coronary syndrome: a short-term prospective cohort study
  44. Riociguat: Something new in pulmonary hypertension therapeutics?
  45. Evaluation of Endothelial and Platelet Derived Microparticles in Patients with Acute Coronary Syndrome
  46. Pattern of Adverse Drug Reactions Reported with Cardiovascular Drugs in a Tertiary Care Teaching Hospital
  47. Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?
  48. Looking into the Crystal Ball—Upcoming Drugs for Dyslipidemia
  49. Novel drug targets in clinical development for heart failure
  50. Pharmacovigilance for psychiatrists: An introduction
  51. Clinical Trial Endpoints in Breast Cancer
  52. Assessment of Arterial Stiffness Index in Hypertensive Patients in Relation to Their Treatment Status Attending a Tertiary Care Center in South India
  53. Noninvasive Nanodiagnostics for Cancer
  54. New and Emerging Drug Molecules Against Obesity
  55. Newer antipsychotics and upcoming molecules for schizophrenia
  56. Globalization of Clinical Trials – Where are We Heading?
  57. Pharmacogenomics of Autoimmune Diseases
  58. The dawn of hedgehog inhibitors: Vismodegib
  59. Pharmacogenomics in Type 2 Diabetes Mellitus and Metabolic Disorders
  60. Clinical trials in India: Where do we stand globally?
  61. Belatacept: A worthy alternative to cyclosporine?
  62. Authors′ reply
  63. Effect of anti-tuberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug